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a b s t r a c t
The ﬁeld of catheter ablation of VT has evolved conceptually and technologically over the past three
decades. From the fundamental understanding of the reentrant mechanism in scar-mediated VT to the
advent and routine implementation of electroanatomic mapping, catheter ablation has emerged from a
palliative last-resort therapy to a more preemptive strategy for patients at risk for arrhythmia
recurrence. An increasing utilization of pre-procedural imaging, high-density mapping, epicardial access,
and more extensive ablation strategies have all contributed to improved clinical success. Advances in
ablation technology and randomized trials are needed to build upon the progress in this growing ﬁeld as
sudden cardiac death from ventricular tachyarrhythmia continues to be the one of leading causes of
death throughout the world.
& 2014 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.
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1. Introduction
Among the spectrum of arrhythmias that are treatable with
catheter ablation, the elimination of reentrant circuits within
ventricular scar remains challenging. As long-term success rates
for AV nodal reentrant tachycardia, bypass-tract tachycardia, and
premature ventricular contractions in the absence of structural
heart disease are 485–90%, intermediate freedom from recurrent
VT at experienced centers has been shown to be 50% at 6–12
months [1,2]. While the vast majority of patients at risk for
recurrent VT have implantable cardioverter-deﬁbrillators (ICD),
ICD therapy is only abortive and does not prevent VT. ICD shocks
are strongly associated with diminished quality of life and
increased mortality [3]. While antiarrhythmics have been shown
to reduce ICD therapies, side effects can be signiﬁcant, prompting
discontinuation in a substantial proportion of patients [4].
At present, surgical and catheter ablation remains the most
effective method to eliminate VT, although further progress in
the ﬁeld is necessary.
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The reasons for ablation failure and recurrence are multi-
factorial. The underlying patient substrate with scar-mediated
monomorphic VT has multiple comorbidities and the severity of
heart failure is associated with increased risk for recurrent VT [1].
Changes in scar biology and the inherent nature of VT, which can
be inconsistently inducible or hemodynamically unstable to pre-
clude activation mapping are important factors. As opposed to
other arrhythmias, the induction of multiple VT morphologies
within scar is common. Importantly, biophysical limitations of
radiofrequency ablation exist in thick ventricular walls that have
transmural circuits, where trabeculations, calciﬁcation, layered
thrombus, and epicardial coronary vessels and fat can all serve
as barriers to effective power delivery into scar.
As a result, strategies have evolved to utilize imaging technol-
ogy and electroanatomic mapping to improve the characterization
and our working understanding of various arrhythmogenic scar
substrates. Other signiﬁcant trends include improving the identi-
ﬁcation of surrogates for critical sites in sinus rhythm, utilizing
hemodynamic support devices to increase the duration of map-
ping in VT, and more comprehensive and extensive of ablation
three-dimensional scar substrates from both the endocardium and
epicardium. In this review, the evolution of ablation of scar-
mediated VT is discussed with focus on current trends.
2. Methods to localize the origin of VT: ECG and Imaging
The most common method to localize the origin of VT is
analysis of the 12-lead electrocardiogram [5,6]. VTs are character-
ized by the QRS morphology and left bundle branch morphologies
originate from the RV or LV septum and right bundle branch VTs
originate from the LV. Sites that originate from superior sites
(anterior wall and outﬂow tracts) exhibit inferior axis and sites
from the diaphragmatic surface of the heart exhibit a superior axis.
Akin to accessory pathway localization, leftward sites of origin are
commonly negative in lead I and septal sites have a tendency to
have leftward vector. The precordial transition is useful in deter-
mining basal versus apical locations, where the mitral annulus is
the most posterior structure (R dominant, early transition) and the
apex is anatomically most anterior (S dominant, late transition)
(Fig. 1).
The width of the QRS is often used to ascertain the distance of the
site of origin from the conduction system. In the absence of anti-
arrhythmics, which result in conduction slowing, VTs with narrow
QRS are located closer to the purkinje system or septum. VTs
originating from the epicardium have been shown to have the widest
QRS morphologies with delayed initial forces due to transmural
activation from outside to inside prior to engaging the conduction
system. Slurring or initial activation delay in the upstroke of the QRS,
and Q waves in the limb leads are suggestive of epicardial sites,
although these criteria may not be speciﬁc in the setting of structural
heart disease [7–9].
The majority of patients that present with scar-mediated VT
have ICDs. Therefore, the clinical presenting VT is seldom captured
with 12-lead electrocardiography. While a far-ﬁeld electrogram
stored in the ICD log can be helpful, signiﬁcant limitations in
identifying and determining the “clinical” arrhythmia exist [10].
Out of practicality, VTs that are reproducibly induced or compar-
able in rate to ICD logs are often considered to be “clinical”. While
the vast majority of VTs originate from regions with scar pathol-
ogy, up to 9% patients with postinfarct scar have VTs from focal
regions typically seen in idiopathic VT cases [11]. Therefore, the
value of NIPS and EP study cannot be understated, taken with the
limitations mentioned previously.
In the setting of ischemic VT, the substrate that typically
harbors reentrant circuits is revealed by Q waves on EKG, wall
motion abnormalities seen on echocardiography, or perfusion
defects on nuclear imaging. Delayed enhancement magnetic
resonance can be helpful in characterizing the transmural location
of scar [12]. Scar patterns in NICM are more typically midmyo-
cardial and epicardial [13], in contrast to ICM, where necrosis from
coronary artery occlusion originates subendocardially [14]. The scar
has a perivalvular and basal lateral wall predilection in NICM [15].
(Fig. 2) The identiﬁcation of scar detected on computed tomography,
magnetic resonance imaging, or positron emission tomography
can be registered and integrated with electroanatomic mapping to
facilitate the targeting of arrhythmogenic scar while depicting
adjacent structures and regional anatomy [16–19].
Fig. 1. Localization of VT based on 12-lead surface electrocardiogram. Superolateral location is suggested by inferior axis with reverse activation of lead I. A basal site of
origin is seen when the precordium is R wave dominant, indicating activation from posterior to anterior, with the mitral annulus being most posterior in the ventricle.
A slurred and delayed upstroke of the QRS is suggestive of an epicardial origin. This is a typical pattern of VT seen in patients with nonischemic cardiomyopathy.
From [100].
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With magnetic resonance imaging, regions of heterogeneity
can be visualized as “gray zones” [20,21]. Current MR technology is
still subject to motion artifacts and partial volume effect and does
not have the resolution of ex-vivo MRI to depict the spatial
complexity of microﬁbrosis [22]. Despite this limitation, studies
have demonstrated speciﬁcity of critical sites to regions of hetero-
geneous ﬁbrosis, where regions of scar that exhibit 425% trans-
murality have been correlated with critical sites during ablation in
ICM and NICM [23,24]. A novel wideband magnetic resonance
sequence to minimize device-related artifacts can increase the
diagnostic yield of imaging, as the majority of patients with scar-
mediated VT have ICDs [25] (Fig. 3).
3. Scar reentry
While polymorphic VT and VF represent spatially dynamic
activation patterns of the ventricle with continuously changing
QRS morphologies, the circuit for monomorphic VT is ﬁxed and
structurally deﬁned by interspersed viable myocardium within
scar. The initial understanding of reentry as the mechanism for VT
was developed in postinfarction substrates. In the 1970s, Joseph-
son et al. described continuous local electrical activity as “localized
ﬁbrillation” during diastole [26]. Reentry as the fundamental
mechanism of arrhythmia was supported by reproducible initia-
tion and termination of monomorphic VT by programmed
stimulation [27]. Subendocardial resection and encircling ventri-
culotomy were shown to result in a signiﬁcant reduction in
recurrent VT and gave further support to the notion that the
modiﬁcation or elimination of critical regions of scar could be an
effective therapy for recurrent VT [28–30]. In 1983, Hartzler et al.
described the ﬁrst catheter ablation using high energy unipolar
direct current shock therapy for right ventricular outﬂow tract VT
and septal infarct-related VT [31]. In the late 1980s, radiofrequency
emerged as the preferred energy source as lesions were more
controlled and homogeneous without any detrimental effects to
global systolic function [32].
4. Entrainment
As the principles of entrainment initially described by Waldo
for atrial ﬂutter could be fulﬁlled by scar-mediated VT, character-
ization of the reentrant circuit provided a central isthmus as a
favorable target [33,34]. In the late 1980s, the collective descrip-
tions of entrainment, or continuous resetting of VT with overdrive
pacing, from regions of slow conduction helped to establish the
gold standard deﬁnition for critical components of a reentrant
circuit [35–39]. The current construct for reentry meandering
between areas of postinfarct ﬁbrosis was popularized by Steven-
son et al. [40]. In this model, the circuit contains an entrance,
central isthmus, and exit, which results in the breakout site that
Fig. 2. Combined endocardial and epicardial mapping of a paient with nonischemic cardiomyopathy revealing more extensive epicardial scar. An epicardial pacemap
desmonstrates an exact match for the targeted VT in the basal lateral scar [98].
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results in formation of the QRS (Fig. 4). Regions of the circuit not
constrained by scar are termed outer loop sites and regions that
are proximal to the entrance and constrained by scar are termed
inner loop sites. Bystander sites are ineffective sites for ablation
and may be remote or attached to the circuit.
The postpacing interval is equal or within 30 ms of the
tachycardia cycle length at any site that is in the reentrant circuit.
Concealed fusion is seen in regions constrained within scar, such
that antidromic capture and collision with the orthodromic
wavefront occurs entirely within the circuit. The stimulus to QRS
exceeds the electrogram to QRS interval at bystander sites
attached to the circuit. The electrogram to QRS interval approx-
imates proximity to the circuit exit, where o30% of the TCL is
distal, 30–70% is central, and 470% is proximal within the
isthmus. The ideal site for ablation within a central isthmus is a
middiastolic potential during VT that exhibits concealed fusion
Fig. 4. Schematic of scar-mediated reentry in a histologic infarction. Diastolic and presystolic slow conduction occurc in the isthmus and activation out of the exit site results
in the QRS morphology. The outer loop is the portion of the circuit that is not bounded by scar [98].
Fig. 3. Reduction of ICD artifact with novel wideband sequence with intergration of delayed enhacement into electroanatomic mapping of anteroseptal scar [25].
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during entrainment with a postpacing interval that is equal to the
tachycardia cycle length (Fig. 5).
As the vast majority of VTs are hemodynamically unstable,
entrainment mapping can only be applied in a limited number of
cases. Therefore, substrate-based ablation strategies during sinus
rhythm were forced to evolve.
5. Electroanatomic mapping and substrate-guided ablation
Since initial validation studies in 1999, electroanatomic map-
ping has become an essential tool to optimize mapping of VT and
to guide ablation lesions. Using a threshold of o1.5 for low
voltage and an arbitrarily deﬁned dense scar threshold of 0.5,
voltage on the surface mapped can be displayed as a three-
dimensional reconstruction. Prior to the advent of electroanatomic
mapping, ﬂuoroscopy was used as a crude method for navigating
the ablation catheter within scar. With scar extent and architecture
displayed on a mapping system, electrogram sites and ablation
lesions can be tagged with a high degree of navigation reproduci-
bility [41]. Two commercially available mapping systems are com-
monly used with magnetic ﬁeld localization (CARTO, Biosense
Webster, Diamond Bar, CA) and impedance-based localization (NAVX,
St. Jude Medical, Minneapolis, MN), although these technologies have
evolved toward incorporating both forms of technologies to optimize
geometry and mapping accuracy. Both of these systems have been
validated in animal models with excellent correlation with gross and
histopathology [42–44] (Fig. 6).
As ablation is often performed in sinus rhythm, accurate and
detailed scar characterization for the delineation of border zones and
identiﬁcation of abnormal electrograms within scar. The placement
of linear lesions guided by electroanatomic mapping was ﬁrst
Fig. 6. High density mapping of epicardial scar in a porcine infarct model using magnetic (left) and impedance-based (right) mapping systems correlate well with gross
pathology [44].
Fig. 5. Entrainment of reentrant VT is seen with concealed fusion when pacing 30 ms faster than the VT cycle length. The postpacing interval from the pacing site is the same
as the tachycardia cycle length and the electrogram to QRS interval is the same as the stimulus to QRS interval. Rapid termination of VT is seen from this critical isthmus site
during radiofrequency ablation.
Adapted from [98].
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described in the 2000 by Marchlinski et al., in patients with
previously termed “unmappable” VT [41]. Higher mapping density
can be achieved with multielectrode catheters and has been shown
to improve the identiﬁcation of late potentials in regions of hetero-
geneity [45]. Multielectrode mapping can expedite VT ablation using
any commonly employed techniques including pacemapping, activa-
tion, and entrainment mapping and may be a more sensitive method
to conﬁrm abolition of late potentials [46] (Fig. 7). All current
mapping systems have evolved to enable and incorporate
multielectrode-capable contact mapping.
6. Epicardial ablation and substrates
A signiﬁcant advancement in the ﬁeld of VT ablation is the
ability to percutaneously access the pericardial for epicardial
mapping and ablation. Initially described by Sosa et al. in 1996
to address arrhythmogenic epicardial scar in patients with Chagas,
this approach has facilitated major conceptual advances in our
understanding of the transmural and epicardial predilection of
scars across various disease states [47]. Further, the presence of
epicardial predominant scar may be an important mechanism for
ablation failure, where ablation from the epicardium allows for a
second dimension of attack in cases where endocardial ablation
alone is inadequate (Fig. 8). Although the incidence of RV puncture
may approach 20%, procedural related mortality and surgical
conversion is exceedingly uncommon [48,49]. Anatomic barriers
to ablation include coronary vessels, epicardial fat, and the left
phrenic nerve [19,50,51]. In its current state, epicardial mapping
and ablation should be performed at experienced centers with
surgical backup. In patients with previous cardiac surgery, surgical
access via a subxiphoid approach or limited anterior thoracotomy
can be performed safely in the EP lab [52,53].
The indications for epicardial mapping are institutionally vari-
able but typically performed after a failed endocardial approach or
if the etiology of cardiomyopathy suggests a high likelihood of
epicardial scar (Fig. 9). Studies of patients with NICM that
underwent combined epicardial–endocardial approach to VT abla-
tion have consistently demonstrated more extensive epicardial
voltage abnormalities compared to the endocardial surface [54–
56]. Similar observations have been made in patients with HCM
and ARVC and a combined epicardial–endocardial approach has
been shown to be more effective than endocardial alone in
observational reports [57–59].
While a combined approach is often used as the initial ablation
strategy in these nonischemic substrates, the yield of epicardial
ablation in the setting of ICM is variable. During surgical mapping
of aneurysms, Josephson et al. reported a paucity of epicardial
late potentials related to VT, suggesting that an endocardial approach
is sufﬁcient for eliminating critical sites [60]. However, the scar
biology of reperfused infarcts is distinctly different from nonreper-
fused infarcts that result in aneurysm formation [61]. Scars that
result from reperfusion are patchier and less extensive in size and
transmurality that result in faster VTs. At our center, patients with
ICM that underwent a combined approach experienced greater
freedom from recurrent VT at 1 year [62,63] (Fig. 10). However, the
majority of patients referred have had prior endocardial ablation,
which introduces a selection bias towards an enriched epicardial
substrate.
In a study of patients without prior ablation, Ouyang demon-
strated a low incidence of epicardial ablation required for clinical
success (6/70 patients), where inferoposterior MI locations most
commonly required an epicardial approach [64]. In patients with
prior failed endocardial ablation, the same group reported the
presence of epicardial substrate in 75% of cases [65]. More
recently, Sarkozy showed that epicardial mapping was performed
in 13% of postinfarction cases, and termination of VT was seen in
6% amongst the entire cohort, but in cases with prior failed
endocardial ablation, epicardial ablation targets were seen in
two-third of patients with ICM. Di Biase et al. demonstrated that
a combined approach was superior to a limited endocardial
strategy, although a more extensive strategy on the endocardium
was applied concomitantly, limiting the ability to isolate the
impact of epicardial ablation alone.
Fig. 7. Contact multielectrode mapping across border zone demonstrates split potentials in dense scar. Pacemapping performed from the 9,10 electrode pair demonstrates a
perfect match for the targeted VT [46].
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7. Hemodynamic support devices
One strategy to improve the targeting of VT during an ablation
procedure is the use of adjunctive hemodynamic support to
increase the ability to apply activation and entrainment mapping
during tachycardia. Termination of VT during radiofrequency
delivery is the most compelling evidence of its elimination, in
comparison to ablating surrogates markers with inferred abolition
of VT through noninducibility on repeated induction attempts.
Various systems have been shown to be feasible including intra-
aortic balloon counterpulsation, retrograde aortic circulatory
pumps (Impella), transseptal circulatory pumps (Tandem Heart)
and femoral bypass [66].
Observational cohort studies have reported greater duration of
time allowed for mapping, with less premature terminations with
pacing or shock therapy, and higher incidences of VT termination
[67,68]. However, the Impella device does not unconditionally
support all VTs, as premature terminations are still required in up
to 20%. Recurrence of VT at 6–12 months has not been shown to be
lower in patients that undergo ablation with hemodynamic sup-
port, suggesting that extensive substrate modiﬁcation in sinus
rhythm is still necessary after termination of an individual VT
Fig. 9. Decision tree for epicardial mapping and ablation on clinical and historical
features of VT and substrate [99].
Fig. 10. Improved freedom from VT in patients undergoing combined epicardial
and endocardial ablation compares to endocardial ablation in patients with
ischemic cardiomyopathy [63].
Fig. 8. Percutaneous access using a Tuohy needle to guide a wire into the pericardial space in LAO projection in a patient with ischemic cardiomyopathy who had recurrence
after endocardial ablation. A late potential identiﬁed in the lateral wall becomes a mid-diastolic potential during VT. Rapid termination of VT is seen after concealed
entrainment is demonstrated.
Adapted from [63].
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[69]. Accordingly, the routine implementation of these devices is
not likely to be cost-effective and further studies on reﬁning patient
selection are needed. Case selection criteria that increase the
likelihood of beneﬁt are patients with decompensated heart failure
and unstable VT with a paucity of ablation targets evident in sinus
rhythm.
8. Ablation strategies – from targeted to homogenization
The techniques and principles originally developed in postin-
farction scar have been translated and applied to patients with
various etiologies of ﬁbrosis and conﬂuent scar including Chagasic
cardiomyopathy, nonischemic cardiomyopathy, arrhythmogenic
RV cardiomyopathy, sarcoidosis, hypertrophic cardiomyopathy,
noncompaction, and surgically repaired congenital heart disease.
However, the electrical footprint for these conditions exhibit
signiﬁcant differences with regard to transmural propensity,
anatomic location, and degree of ﬁbrosis [56].
Various ablation strategies have been implemented to elim-
inate critical reentrant circuits within scar. There is no uniform
agreement on the optimal ablation strategy and the number of
targets within the substrate and hemodynamic tolerance of VT
often dictates the procedural approach. Our approach to ablation is
summarized in Fig. 11. High-density delineation of scar is ﬁrst
performed and regions of slow conduction, as evidenced by
fractionated or late potentials are tagged and pace mapped to
assess for a relation with the targeted VT. Pacemapping can be an
effective method to focus ablation to speciﬁc regions within scar
that exhibit a morphologic match to the targeted VT. Pace maps
with stimulus-QRS delays (440 ms) are more speciﬁc as conduc-
tion slowing out of scar and sites that exhibit multiple QRS
morphologies may suggest a common conducting channel
[70,71]. The initiation of VT during pacemapping (pace mapped
induction) can be seen when pacing from an isthmus and
successful termination is seen in 490% of cases.
When VT is not inducible or hemodynamically unstable,
activation and entrainment mapping cannot be performed. There-
fore, “substrate-based” ablation lesion sets within scar guided by
electroanatomic mapping are commonly employed. (Fig. 12) Short
linear lesions guided by electroanatomic mapping were ﬁrst
demonstrated to be effective at reducing recurrent VT [2,41,72].
Ablation at the interface between normal and low voltage areas
has the potential to close off exits from channels originating deep
within scar. Hsia et al. demonstrated by entrainment mapping
within different regions of scar that 84% of isthmus sites were
localized to dense scar, whereas Vera et al. correlated isthmus sites
proven by entrainment mapping to border zone tissue in 68%
[73,74]. “T-shaped” lesions were implemented in SMASH-VT at
the border zone of a good pacemap site, with perpendicular linear
ablation into scar to potentially ablate deeper in a conducting
channel [75].
As areas of slow conduction within scar serve as the requisite
substrate for reentry, the identiﬁcation of locally uncoupled and
delayed local electrograms, or late potentials is an important strategy
during mapping in sinus rhythm. Delayed and isolated late potentials
have been shown to have speciﬁcity for induced VTs and ablation
aimed at eliminating these abnormal electrograms improves clinical
freedom from VT [76,77]. Late potentials have been shown to be more
speciﬁc for critical sites than macroscopic voltage channels visualized
by lowering voltage thresholds [78,79]. Regions of localized delayed
conduction may not always manifest with ﬁxed conduction slowing
after the QRS offset, as many critical sites are functionally inﬂuenced
by anatomic location, wavefront, and rate, where an extrastimulus
can reveal uncoupled local activation [77,80–82].
Extensive and diffuse ablation, or “scar homogenization” aimed to
eliminate all abnormal electrograms within postinfarct scar is an
important trend seen in VT ablation [83,84]. While the elimination of
all electrograms has been shown to be more predictive of clinical
success than inducibility, it may be difﬁcult to achieve in large scar
substrates [81]. Ablation targeting earlier late potentials may elim-
inate or modify downstream activation of a channel and expedite
homogenization strategies [85,86]. Consistent with the trend to
Fig. 11. Ablation strategy for scar-mediated VT at our institution. VT is induced at the start of the procedure and entrainment is performed if hemodynamically tolerate. All
abnormal potentials are tagged and pacemapped with observation for matches and functional responses like multiple exit sites of pacemapped inductions. The intended
elimination of all abnormal electrograms serves as the endpoint after a targeted approach is completed [71].
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ablate scar more extensively, many institutions ﬁrst target the scar
and induce VT after homogenization is performed, whereas others
maintain a targeted approach ﬁrst to eliminate the clinical VT before
diffuse ablation is undertaken.
9. Procedural endpoints
The most commonly employed electrophysiological endpoint is
the achievement of noninducibility. While noninducibility has
been shown to be predictive for clinical freedom from recurrent
VT, it has not been uniformly the case [1,2]. Inducibility of VT is
probabilistic and rarely is reproducibly triggered on command.
Further, anesthesia and antiarrhythmics may adversely impact the
ease of VT induction. In one of the largest cohorts published to
fate, Della Bella demonstrated that acute procedural endpoints
were predictive of cardiovascular mortality [87].
As homogenization is increasingly being performed, an objec-
tive measure to demonstrate complete elimination of abnormal
electrograms has not been established. Use of a multipolar map-
ping catheter may be useful to rapidly remap ablated regions to
ensure abolition of late potentials [88]. In many cases, biophysical
limitations may impair the ability to completely eliminate an
electrogram. In other arrhythmias treated with linear lesions,
bidirectional block has been shown to be the most robust electro-
physiological endpoint. Potential objective endpoints would
require remapping to demonstrate a change in scar propagation
that would reﬂect a line of block or elimination of the latest
regions of activation.
10. Ablation technology and intramural substrates
With increased implementation of epicardial ablation, radio-
frequency energy delivered into scar from both surfaces of the
myocardial wall has improved our ability to penetrate and modify
scar. Irrigated ablation technology has been shown to optimize
power delivery into tissue as heating of the catheter-tissue inter-
face is mitigated. Cryoablation has been shown to create similar
lesions dimensions on the epicardium and it often used in open
surgical cases [89,90]. However, irrigated lesions delivered
through ﬁbrosis may still be limited.
Myocardial regions that speciﬁcally remain a challenge are
septal substrates and the LV summit. Bipolar radiofrequency
ablation has been proposed to improve the depth of ablation
lesions [91]. A retractable intramural needle, that can be inserted
up to 8 mm deep into the myocardium holds promise for tackling
difﬁcult substrated [92]. Alcohol and coil embolization of a feeding
arterial branch to the targeted region have demonstrated efﬁcacy
[93,94]. Alternative energy sources like HIFU require technical
optimization but may have a future role in VT ablation.
11. Randomized trials and guidelines
Over the past two decades, there have been a paucity of
randomized trials in VT ablation. This is attributable in part to
referral bias and the inherent urgent nature of recurrent VT, which
frequently presents as electrical storm. SMASH-VT was an inves-
tigator initiated randomized trial of 128 patients greater than
1 month postinfarction with a secondary prevention indication for
Fig. 12. Spectrum of substrate-based ablation lesion sets employed for scar modiﬁcation in sinus rhythm. Border zone ablation with T-shaped lesions was the predominant
strategy in SMASH-VT whereas linear transecting lesions were performed in EURO-VT. Homogenization involves more extensive ablation and may results in more diffuse
substrate modiﬁcation.
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ICD comparing preemptive ablation versus standard medical
therapy [75]. After the study commenced, patients with primary
prevention with an appropriate therapy were included to facilitate
enrollment. Using a substrate based approach and entrainment
when possible, patients that underwent preemptive catheter
ablation had a signiﬁcant reduction in ICD therapy at 2 years
compared to those receiving medical therapy (12% vs. 33%, HR
0.35, p¼0.007).
The VTACH study was a prospective, randomized multi-center
European trial examining the role of preemptive VT ablation prior
to implantation of ICD for hemodynamically stable VT with prior
infarction and EF o50% [95]. In 107 patients randomized, survival
free of VT was 47% in the ablation group and 29% in the control
group at 2 years (HR 0.61, p¼0.045).
Although these studies were not powered to assess for mor-
tality, they advanced the notion of catheter ablation as an upfront
strategy as opposed to a palliative procedure of last resort.
Accordingly, the updated guidelines for VT ablation recommend
ablation to be timed well before multiple ICD therapies ensue [96].
It should be noted that epicardial ablation was not performed in
these two studies and the results can only be generalized to
postinfarct substrates.
The STAR-VT trial is a randomized trial examining the role of
ablation in patient with an indication for ICD implantation [97].
The inclusion criteria targeting 562 patients with secondary
prevention indications as well as primary prevention patients
with inducible VT, where nonischemic cardiomyopathy patients
will be included and epicardial ablation is encouraged.
12. Conclusions
There have been signiﬁcant advancements in the ﬁeld of VT
ablation since the appreciation of reentry within scar as the
underlying arrhythmic mechanism. Our understanding of various
scar substrates has improved signiﬁcantly due to imaging technol-
ogy and percutaneous epicardial access. A trend toward multi-
electrode catheter mapping facilitates higher resolution mapping
of scar and can be employed with any technique implemented
during ablation. The ability to understand the second dimension of
spatially complex three-dimensional scar has been greatly facili-
tated by percutaneous access to the pericardial space and multiple
cohort studies have shown improved outcomes with combined
epicardial–endocardial strategies. More extensive and diffuse
ablation strategies aimed to “homogenize” scar may continue to
improve clinical outcomes as this more closely mimics surgical
resection of arrhythmogenic scar tissue. Midmyocardial, or intra-
mural sites of origin remain a challenge and new technologies are
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